NCT00101270: Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
|
|
| Completed | 1 | 24 | US | irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP | National Cancer Institute (NCI) | Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Melanoma, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific | 09/07 | | | |
NCT02574663: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors |
|
|
| Completed | 1 | 66 | US | TGR-1202, nab-paclitaxel + gemcitabine, Abraxane (nab-paclitaxel) + Gemzar (gemcitabine), Oxaliplatin + Folinic acid + Fluorouracil, Eloxatin (Oxaliplatin) + Leucovorin (Folinic acid) + 5-FU (Fluorouracil), Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab, Eloxatin (Oxaliplatin) + Leucovorin (Folinic acid) + 5-FU (Fluorouracil) + Avastin (Bevacizumab) | TG Therapeutics, Inc., SCRI Development Innovations, LLC | Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST) | 08/18 | 08/18 | | |
| Recruiting | 1 | 1200 | Europe, Canada, Japan, US, RoW | Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus | Amgen | Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation | 12/26 | 12/27 | | |
